Core Viewpoint - Oncternal Therapeutics, Inc. plans to file a Form 25 Notification of Delisting with the SEC on March 17, 2025, to remove its securities from Nasdaq listing and subsequently deregister with the SEC [1][2] Group 1: Delisting and Deregistration Process - Nasdaq suspended trading of Oncternal's common stock on December 3, 2024, and notified the company about the Form 25 filing [1] - Following the delisting, Oncternal will file a Form 15 to deregister with the SEC, which will suspend its obligation to file periodic reports immediately [2] - The company's duty to file any other reports required by the Exchange Act will terminate 90 days after the Form 15 filing [2] Group 2: Company Overview - Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies for cancers with critical unmet medical needs [3] - The company targets promising biological pathways involved in cancer generation or progression, with a focus on hematological malignancies and prostate cancer [3]
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC